Print Page   Close Window

Press Release

POZEN Names Dr. Marshall Reese Executive Vice President, Product Development

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Oct. 19, 2004--POZEN, Inc. (NASDAQ: POZN) announced today the appointment of Marshall E. Reese, Ph.D., a veteran executive with more than 25 years of international research and development experience, as executive vice president, product development. Dr. Reese will be responsible for overseeing all of the company's product development activities. He will report to John R. Plachetka, Pharm. D., chairman, president, and chief executive officer and will be a member of the executive committee.

"Marty's in-depth knowledge of the pharmaceutical industry, particularly in clinical development and program management, makes him a strong addition to our senior management team," said Dr. Plachetka.

Dr. Reese was most recently employed at the Swiss-based pharmaceutical company Novartis as senior vice president and global head of research and development, Consumer Health Care. Prior to joining Novartis in 1999, Dr. Reese held several senior executive positions at Glaxo Inc. and GlaxoWellcome, including vice president of global OTC development and manufacturing with GlaxoWellcome, based in the United States, and vice president of development planning and international OTC strategies for Glaxo and GlaxoWellcome, in both the United States and the United Kingdom.

During his tenures with Glaxo and Novartis, Dr. Reese was responsible for managing the switch from prescription to over-the-counter medications for Lamisil topical, Voltaren and Nicotine patches in Europe, Middle East Africa, and Japan, and for Beconase AQ, Zovirax and Zantac 75 in Europe. Additionally, he managed the regulatory approval process for Augmentin, Beconase AQ, Ventolin Rotocaps, and Ventolin Syrup in the United States.

Dr. Reese received his B.S., M.S., and Ph.D. degrees from the University of Tennessee at Knoxville.


POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. Since its inception, POZEN has focused its efforts primarily on the development of pharmaceutical products for the treatment of migraine. POZEN has development and commercial alliances with GlaxoSmithKline, Xcel Pharmaceuticals, and Nycomed. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website: www.pozen.com.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies, or the failure to obtain such approval of our product candidates; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2004 under "Management's Discussion and Analysis of Financial Condition and Results of Operations." We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

Bill Hodges, 919-913-1030
Chief Financial Officer
Fran Barsky, 919-913-1044
Director, Investor Relations